Bookmark and Share
Australian Prescriber
  • Home
  • About us
    • Who we are
    • What we do
    • Editorial executive committe
    • Advisory editorial panel
    • AP Video
  • Contact us
    • Subscription
    • Email alert
    • Write to Australian Prescriber
  • Index
    • Subject index
    • Author index
  • For consumers
    • Comments
    • Articles
    • Patient perspectives
    • Support organisations
    • News
  • Archive
    • Back Issues
    • Media releases
    • Past covers
Volume 22 Number 4 - August 1999
Editorial
Advertising pharmaceuticals to Australians
(Editorial) J. Donovan
-
Letters to the editor
-
The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines
E. E. Roughead
-
Complaints: a personal view
-
New antipsychotic medications
J. McGrath & P. White
-
Patient support organisation
Schizophrenia Fellowship
-
Stroke in the era of evidence-based medicine: Australian comment
E. G. Stewart-Wynne
-
Oral extended-release products
L. N. Sansom
-
Abnormal laboratory results
Hepatitis C: diagnosis and monitoring
D. J. Siebert, A. M. Breschkin, D. S. Bowden & S. A. Locarnini
-
New drugs
basiliximab
capecitabine
cerivastatin sodium
imiglucerase
raloxifene hydrochloride
recombinant factor VIIa
tirofiban hydrochloride
ursodeoxycholic acid

-
Your questions to the PBAC
Prescriptions for flutamide and bicalutamide
-
Get Adobe Acrobat
Australian Prescriber Cover
HomeHome Contact usContact us Free subscriptionFree subscription Useful linksUseful links User guideUser guide Legal informationLegal information Privacy noticePrivacy notice Web manager